NASDAQ:AGIO

Agios Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy AGIO

*Your capital is at risk

$40.55

-0.680 (-1.65%)

At Close: Jul 13, 2026

Agios Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 14.88. In total, the insiders bought 904.54K and sold 68.48K AGIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	14.88
● Buy	904.54K shares
● Sell	68.48K shares
84% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Jun 18, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 08, 2026 Buy	Common stock A-Award	Backstrom Jay T. Director	Director	1 447 Value: $61.9K
Jul 08, 2026 Buy	Restricted stock units M-Exempt	Backstrom Jay T. Director	Director	1 447 Value: $61.9K
Jul 01, 2026 Buy	Common stock M-Exempt	Gheuens Sarah Chief Medical Officer	Officer	8 375 Value: $310.5K
Jul 01, 2026 Buy	Restricted stock units M-Exempt	Gheuens Sarah Chief Medical Officer	Officer	8 375 Value: $310.5K
Jul 01, 2026 Sell	Common stock S-Sale	Gheuens Sarah Chief Medical Officer	Officer	4 007 Value: $150.5K
Jun 18, 2026 Buy	Stock options (right to buy) A-Award	Fouse Jacqualyn A Director	Director	14 950 Value: $510.7K
Jun 18, 2026 Buy	Restricted stock units A-Award	Fouse Jacqualyn A Director	Director	2 927 Value: $100.0K
Jun 18, 2026 Buy	Restricted stock units M-Exempt	Fouse Jacqualyn A Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Restricted stock units M-Exempt	Ho Maykin Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Stock options (right to buy) A-Award	Owen Adams Catherine Director	Director	14 950 Value: $510.7K
Jun 18, 2026 Buy	Common stock M-Exempt	Owen Adams Catherine Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Restricted stock units M-Exempt	Owen Adams Catherine Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Restricted stock units M-Exempt	Scadden David Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Common stock M-Exempt	Smith Cynthia Director	Director	2 816 Value: $96.2K
Jun 18, 2026 Buy	Stock options (right to buy) A-Award	Smith Cynthia Director	Director	14 950 Value: $510.7K
Jun 18, 2026 Buy	Performance share units M-Exempt	Goff Brian Chief Executive Officer	CEO / President	39 000 Value: $1.33M
Jun 18, 2026 Buy	Restricted stock units A-Award	Goff Brian Chief Executive Officer	CEO / President	39 000 Value: $1.33M
Jun 18, 2026 Buy	Performance share units M-Exempt	Burns James William Chief Legal Officer	Officer	3 000 Value: $102.5K
Jun 18, 2026 Buy	Restricted stock units A-Award	Burns James William Chief Legal Officer	Officer	3 000 Value: $102.5K
Jun 18, 2026 Buy	Restricted stock units A-Award	Milanova Tsveta Chief Commercial Officer	Officer	3 000 Value: $102.5K
Jun 18, 2026 Buy	Performance share units M-Exempt	Gheuens Sarah Chief Medical Officer	Officer	3 000 Value: $102.5K
Jun 18, 2026 Buy	Restricted stock units A-Award	Gheuens Sarah Chief Medical Officer	Officer	3 000 Value: $102.5K
Jun 18, 2026 Buy	Stock options (right to buy) A-Award	Backstrom Jay T. Director	Director	14 950 Value: $510.7K
Jun 18, 2026 Buy	Restricted stock units A-Award	Backstrom Jay T. Director	Director	2 927 Value: $100.0K
Jun 18, 2026 Buy	Common stock M-Exempt	Ballal Rahul D. Director	Director	2 816 Value: $96.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AGIOS PHARMACEUTICALS

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...

Read Full Profile Here